A Study of LJPC-501 in Pediatric Patients With Hypotension
Status:
Completed
Trial end date:
2018-04-14
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the effect of LJPC-501 infusion on mean arterial
pressure (MAP) or reduction in sum norepinephrine (NE) equivalent dosing, at Hour 2 after the
start of LJPC-501, in pediatric patients who remain hypotensive despite receiving fluid
therapy and vasopressor therapy. In addition, this study will evaluate the safety and
tolerability of LJPC-501 in pediatric patients, the change in MAP over 24 hours after the
start of LJPC-501, the change in serum lactate concentrations, and the change in Pediatric
Logistic Organ Dysfunction (PELOD) scores.